Scott Davies Sells 615 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the transaction, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This represents a 2.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

NASDAQ:ILMN opened at $176.55 on Friday. The firm has a market capitalization of $26.71 billion, a PE ratio of 32.10, a PEG ratio of 3.32 and a beta of 1.50. The stock’s fifty day moving average is $149.62 and its 200 day moving average is $137.66. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $182.84. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the firm earned $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Barclays increased their price objective on shares of Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research report on Wednesday. Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina presently has an average rating of “Hold” and a consensus target price of $146.00.

Institutional Investors Weigh In On Illumina

Several large investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC bought a new stake in shares of Illumina during the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund bought a new position in Illumina in the fourth quarter worth approximately $26,000. Creative Capital Management Investments LLC increased its holdings in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new position in Illumina during the 4th quarter worth $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in Illumina during the 4th quarter valued at $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.